Regeneron Co-Chief Scientific Officer Andrew J. Murphy Reports $12.9 Million Disposal of Common Shares

• Regeneron Pharmaceuticals Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 common shares on October 14, 2026.
• Murphy exercised non-qualified stock options for 17,000 common shares at $381.92 per share on October 13, 2026.
• He also disposed of 12,853 common shares at $754.58 per share on October 13.
• Following the transactions, Murphy held 47,833 common shares directly, with another 4,414 shares held indirectly through a 401(k) plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001796226-26-000002), on October 15, 2026, and is solely responsible for the information contained therein.